Indivior Q4 earnings beat; SUBLOCADE rev $252M (+30%); new $400M buyback; FY26 guidance reaffirmed

Indivior Pharmaceuticals, Inc.

2025-FY EPS reported $1.64 revenue$1,239,000,000

Q4 total net revenue $358M (+20% YoY); SUBLOCADE net revenue $252M (+30%); GAAP diluted EPS $0.79 vs $0.17
Non-GAAP Q4 net income $107M ($0.82 diluted EPS); Adjusted EBITDA $142M (+91% YoY)
FY 2025: revenue $1,239M (+4%), SUBLOCADE $856M (+13%); GAAP net income $210M ($1.64 EPS); adj. EBITDA $428M (+20%)
Board authorized new $400M share repurchase program (up to 18 months) for opportunistic deployment
FY 2026 guidance: SUBLOCADE $905M-$945M, adj. EBITDA $535M-$575M, non-GAAP opex $430M-$450M

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.